Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a ...
SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
OCTOBER 21, 2024, NEW YORK – Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying ...
WALTHAM, MA - April 23, 2026 - - KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results